Trial Profile
A randomized, double-blind, parallel-group, multicenter study to compare the glycemic effects, safety, and tolerability of exenatide long-acting release (once weekly) to those of sitagliptin and a thiazolidinedione in subjects with type 2 diabetes mellitus treated with metformin.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jul 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Pioglitazone; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DURATION-2
- Sponsors Amylin Pharmaceuticals
- 05 Oct 2018 Results assessing the efficacy and safety of exenatide once weekly across 10 comparator-controlled studies from the DURATION clinical programme (n=2251) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 01 Apr 2018 Results of pooled post hoc analysis of this and other ten trials assessing the relationship of heart rate changes with baseline heart rate and identifying patient characteristics associated with changes in heart rate in the Exenatide QW development program published in the Diabetes Therapy
- 28 Jun 2011 Pooled efficacy analysis results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.